الفهرس 
EPIDEMIOLOGY OF NON-HODGKIN LYMPHOMAOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
Diffuse large B‐cell lymphoma is the most common subtype of NHL accounting for about 25% to 30% of all NHLs worldwide. It results from the malignant proliferation of B cells during their different stages of development. The primary site of DLBCL is important in determining the clinical features, the treatment options, and the disease variable outcomes.
Analyzing the clinical, epidemiological features and treatment outcomes including response, toxicity, and survival rates (DFS, PFS &OS) in DLBCL adult patients treated at clinical oncology department, Ain Shams University hospitals.
This retrospective cohort study was conducted on 78 DLBCL adult patients who were treated at Ain Shams clinical oncology department in the period from January 2016 to December 2019. Depending on the site of the disease involvement, Patients were categorized into three groups; nodal-only group, extranodal-only group, and both nodal & extranodal group. Patients’ demographic and clinical data were collected and analyzed together with results of laboratory and radiological investigations in addition to received treatment and follow-up data.
In the 78 patients, the mean age at presentation was 45.54 ±15.38 years, 48.7% of the patients were 40-60 years old with female predominance comprising 57.7%. Patients from urban areas comprised 76.9% of the total cohort. Only 37.2% of patients were smokers. The most commonly reported comorbidity was hypertension (24.4%) and the most commonly reported viral infection was HCV (21.8%). Swelling was the most commonly presented symptom comprising 42.3% and DLBCL NOS was the most commonly reported subtype comprising 64.1% of all cases. B-symptoms were positive in 29.5% of the patients and LDH serum level was high in the majority of the patients comprising 73.1%. Bulky disease was reported in 38.5% of the patients.The majority of the patients presented with ECOG PS (0-1) comprising 74.4% and half of the patients were presented in advanced stages (III – IV).